Roumai Medical
Developing next-generation biotechnologies in regenerative medicine and human-machine interface.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
Operating at the intersection of regenerative medicine and biotechnology, Roumai Medical is a dual-headquartered enterprise aiming to address complex medical needs through advanced therapies. The company was founded in 2021, establishing its corporate and GMP laboratory headquarters in Shenzhen, China's Nanshan Innovation Biopark, a hub for high-tech development. A European innovation and R&D center is located at the EPFL Innovation Park in Lausanne, Switzerland, fostering collaboration between academia and industry. The company was founded by CEO Shiyu Cheng and COO Ivan Istomin.
Roumai Medical's core business revolves around the development and manufacturing of bio-integrative medical devices, primarily focusing on tissue-engineered solutions. The company's flagship product is the off-the-shelf, tissue-engineered blood vessel, "RegeneVessel," designed for patients with cardiovascular conditions such as coronary and peripheral artery diseases. These artificial vessels, developed for small diameters between 2 and 6 millimeters, are created to be biocompatible and support self-remodeling, which may reduce the risk of rejection compared to traditional grafts. The technology leverages advanced biomaterials that mimic the natural extracellular matrix to promote a patient's own cells to attach, grow, and differentiate. These materials are designed to degrade at a controlled rate while releasing bioactive signals that aid in tissue repair.
Utilizing synthetic biology, the company engineers cells, proteins, and genetic circuits to create its products. This approach extends to producing personalized collagen by programming cells to match specific genetic profiles, which can enhance tissue structure and wound healing for both medical and cosmetic applications. A notable development is the integration of electrodes into these bio-fabricated blood vessels, allowing for continuous blood flow measurement and electrical stimulation for applications like gene transfection. The company's business model appears to be B2B, focusing on providing these advanced therapeutic products to healthcare providers and systems. The company has received funding from investors including Puhe Capital and K2VC, and has participated in accelerator programs with VentureLab.
Keywords: regenerative medicine, tissue engineering, artificial blood vessels, biomaterials, synthetic biology, cardiovascular devices, collagen synthesis, human-machine interface, medtech, biotech, cell therapy, advanced therapies, implantable medical devices, RegeneVessel, tissue regeneration, vascular disease treatment, personalized medicine, bio-integrative devices, GMP laboratory, life sciences